MiniOmni Sunlight

MiniOmni is based on Omnipath quantitative ultrasound technology, which measures the speed of ultrasound waves along the bone’s maximal strength axis, eliminating soft tissue effects and ensuring precise and reproducible results.

Key Features of MiniOmni:

• Safety and non-invasiveness:
  Uses ultrasound technology, avoiding exposure to ionizing radiation and ensuring a safe experience for the patient.

• High precision:
  Based on Sunlight’s proprietary Omnipath™ technology, it delivers highly accurate measurements and allows multi-site assessments, improving diagnostic accuracy in osteoporosis screening.

• Compact design:
  With dimensions similar to a book and minimal weight, MiniOmni is easily portable — ideal for use in diverse clinical environments, including medical offices and pharmacies.

• USB connectivity:
  Easily connects to a computer via a USB port.

• Fast and complete results:
  Provides WHO-compliant outputs, including T-score and Z-score, with graphical reports that include patient details and measurement history.

MiniOmni represents an innovative and practical solution for the early evaluation of osteoporosis, offering numerous benefits to healthcare professionals engaged in bone health prevention programs:

• Cost efficiency:
  The device’s low acquisition cost and absence of disposable materials significantly reduce operational expenses, making MiniOmni a cost-effective solution for bone density assessment.

• Ease of use:
  An intuitive interface and rapid data acquisition allow healthcare providers to conduct screenings efficiently, improving workflow and increasing the number of patients evaluated.

• Portability:
  Thanks to its compact and lightweight design, MiniOmni is suitable for various environments — from traditional clinics to home visits, community screening programs, and telemedicine applications.

MiniOmni Sunlight can perform measurements at multiple skeletal sites through the use of multi-site software and different ultrasound probes, each designed for specific anatomical areas:

• Radius/Tibia Probe:
  Measures the Speed of Sound (SOS) at the distal radius.
  Supplied as standard with the MiniOmni system, it assesses bone density at the radius — a site chosen for its accessibility and reliability in osteoporosis diagnostics.
  With the multi-site software, the same probe can also be used for tibial measurements.

• Phalanx Probe:
  Measures SOS at the proximal phalanx of the third finger.
  This allows assessment of bone density in the fingers, offering an alternative when other sites are inaccessible or inappropriate.

• Metatarsal Probe:
  Measures SOS at the fifth metatarsal.
  Particularly useful for evaluating weight-bearing bones, providing additional information about fracture risk.

The flexibility of the multi-site system enhances the identification of osteoporotic sites and allows testing of patients for whom certain skeletal regions are difficult to assess.

MiniOmni includes advanced software with an intuitive interface, designed to facilitate bone density measurement and analysis while providing easy-to-read diagnostic reports.

Connection to a computer via USB port ensures fast data transfer, simplifying data storage and analysis within the software.

The software generates detailed, easy-to-interpret reports, including:

• Measurement results:
  Displays T-score and Z-score values compliant with World Health Organization (WHO) guidelines, providing a clear indication of the patient’s bone density relative to reference values.

• Graphical representations:
  Visual charts that help patients understand results and assist physicians in explaining bone health conditions.

• Patient history:
  Archives past measurements to monitor bone density trends and evaluate treatment effectiveness over time.

MiniOmni Sunlight is supported by robust scientific evidence and regulatory approvals, confirming its reliability and accuracy in bone density assessment — making it a trusted tool for early diagnosis and ongoing monitoring of osteoporosis.

• Regulatory approval:
  In 2011, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance, confirming that MiniOmni meets required safety and performance standards for clinical use.

• Omnipath™ Technology:
  Measures the Speed of Sound (SOS) through bone — a method validated in thousands of Omnisense system installations worldwide, proving its high precision and reproducibility.

• Ethnic reference databases:
  To ensure accurate and representative results, MiniOmni includes population-specific reference databases for Caucasian, Asian, North American, and Latin American groups, collected from multiple geographic regions.
  This enables ethnically adjusted bone density evaluations.

• WHO compliance:
  Provides diagnostic results consistent with World Health Organization (WHO) criteria for osteoporosis, including T-score and Z-score thresholds.